25C-NBOMe is currently Schedule I in the United States. This went into effect on November 15, 2013.
Addictive Potential: Unknown
Emergency Room Visits Yearly: Unknown
Mandatory Minimum Sentence: Unknown
Mechanism of Action: 5HT2A receptor partial agonist
25C-NBOMe is also known as 2C-C-NBOMe, NBOMe-2C-C, 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, and 4-chloro-2,5-dimethoxy-N-(2 methoxybenzyl)phenethylamine.
Reports from recreational users suggest 2C-C-NBOMe to be an active hallucinogen at insufflated dosages ranging from 25-700 μg (Erowid, 2013).
Side Effects & Adverse Reactions:
25C-NBOMe is a very new substance, and little is known about its side effects, adverse reactions, long term damage, and/or addiction potential. Remember, research chemicals are experimental chemicals that are not approved for human consumption. This is because not enough data exists currently about their effects in humans. Although some people are willing to ingest research chemicals, it is unreasonable to assume that they are in any way safe to use recreationally.
Teen allegedly killed by new chemical drug - In April, 2013, two teens in Fredericksburg, Texas, consumed a legal substance thought to be 25c-NBOMe. One of them died, and the other was hospitalized but recovered.
According to Erowid (2013), “Due to its potency, misjudging the dose of 2C-C-NBOMe carries very real risks. A substantial dosage error could lead to undesirable or dangerous effects. If 2C-C-NBOMe is in in pure powder form, small breezes, accidental inhalation, or touching the eyes or mouth after handling could result in full-blown effects or dangerous overdoses. Because of these dangers, 2C-C-NBOMe powder should be labeled clearly and handled with laboratory methods (goggles, gloves, mask) to minimize risks.”